Pfizer Inc. (PFE)
Dopo ore: 07:59PM EDT
| Chiusura precedente | 41,67 |
| Aperto | 41,90 |
| Denaro | 41,45 x 3200 |
| Lettera | 41,53 x 4000 |
| Min-Max giorno | 41,38 - 42,03 |
| Intervallo di 52 settimane | 32,83 - 51,86 |
| Volume | 23.208.697 |
| Media Volume | 32.979.353 |
| Capitalizzazione | 232,622B |
| Beta (5 anni mensile) | 0,69 |
| Rapporto PE (ttm) | 17,72 |
| EPS (ttm) | 2,34 |
| Prossima data utili | 02 nov 2021 |
| Rendimento e dividendo (forward) | 1,56 (3,74%) |
| Data ex dividendo | 04 nov 2021 |
| Stima target 1A | N/D |
- GlobeNewswire
Voyager Therapeutics Announces License Option Agreement with Pfizer for Next-Generation TRACERᵀᴹ AAV Capsids to Enable Neurologic and Cardiovascular Gene Therapy Programs
Voyager receives $30 million up front with potential option exercise fees and milestone payments of up to $600 million plus product sales-based royalties Pfizer receives transgene-specific access to Voyager’s novel AAV capsids with enhanced blood-brain-barrier penetration and cardiac muscle tropism for potential use with two transgenes CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next
- GlobeNewswire
Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency
NEW YORK and MIAMI, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for somatrogon, a once-weekly long-acting recombinant human growth hormone, for the treatment of growth hormone deficiency (GHD) in pediatric patients. The Prescription Drug User Fee Act (PDUFA) goal date has been extended by three months to Janu
- FX Empire
Pfizer Close to Long-Term Buying Opportunity
The pullback into September is now approaching a zone of strong support near 40.
